Big biotech, Big pharma, Biotech, Diagnostics, M&A, Pharma

Roche has acquired a cancer drug for $65.8 million

Posted on 15 October 2014

Tags: , , ,

Roche has acquired from Wilex the rights to an undisclosed cancer drug for as much as $65.8 million.

Wilex desperately needs the money to stay afloat after a year that has seen it rocked by a failed drug trial and a wholesale auctioning of its assets to foreign partners.

It slashed 80 percent of its workforce in January and had its CEO step down shortly thereafter.

It is now attempting to exit the development business, a process that makes today’s news all the more relevant.

Roche will receive exclusive rights to the unnamed cancer target and will expand its relationship with Wilex subsidiary Heidelberg Pharma.

Heidelberg currently handles the out-licensing for Wilex’s proprietary anti-body drug conjugate therapies.

For further deal information visit Current Agreements (subscription required)

Related

Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary

Report: Pharma and Biotech M&A Trends 2009-2014

Browse: Complete Current Partnering report catalog

View: M&A Scorecard in CP Insight– view top life science partnering deals by value

View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making

View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply